Shares of Annovis Bio Inc (NYSE AMERICAN: ANVS) are up over 27% on Thursday after the company announced the European Patent Office has granted it’s patent for a method of treating acute nerve and brain injuries by administering ANVS405 after injury.
“This new patent, covering acute indications, joins our two patents covering our primary disease targets, AD and PD, which both originate from a patent family that claims ANVS401 for the treatment of neurodegenerative diseases,” commented Maria Maccecchini, CEO of Annovis.
However, the Pennsylvania-based company said that while Europe has allowed the whole acute injury patent, the US Patent and Trademark Office (USPTO) has asked them to split the original application into several patents. The company has now filed divisional applications covering individual diseases that the drug targets, such as traumatic brain injury, stroke, and spinal cord injury.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
They expect to receive additional patent allowances in the future.
Annovis Bio shares reacted positively to the news, currently trading 27.68% higher at $23.20 premarket.
